TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37648579

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg once daily in addition to standard of care therapy
Number of subjects: 4000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4000
Study: 37648977

Group type: EXPERIMENTAL
Intervention: Vega Exercise Community (group-based exercise sessions, 3 times a week for 4 months)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Vega Exercise Community
Number of subjects: 400

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 400
Study: 37648990

Group type: EXPERIMENTAL
Intervention: CDT low-score group (score ≤ 5/8)
Number of subjects: 93

Group type: COMPARATOR
Intervention: CDT high-score group (score ≥ 6/8)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 93
Study: 37649005

Group type: EXPERIMENTAL
Intervention: Lifestyle interventions with weight-loss
Number of subjects: 2220
Study: 37649092

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical diaphragmatic stimulation (TEDS)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: TEDS
Number of subjects: 66
Study: 37649617

Group type: EXPERIMENTAL
Intervention: COVID-19 vaccination
Number of subjects: 13000

Group type: EXPERIMENTAL
Intervention: Moderna mRNA-1273 vaccine
Number of subjects: 13000

Group type: EXPERIMENTAL
Intervention: Healthcare worker occupation
Number of subjects: 13000
Study: 37649695

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 37650231

Group type: EXPERIMENTAL
Intervention: Novel therapeutics for the treatment of early COVID-19, specific interventions not detailed.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified.
Number of subjects: 0
Study: 37650232

Group type: EXPERIMENTAL
Intervention: Moderate/severe immunocompromise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immunosuppression
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonimmunocompromised individuals
Number of subjects: 0
Study: 37650230

Group type: EXPERIMENTAL
Intervention: Monoclonal antibodies (mAbs)
Number of subjects: 2115

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2115
Study: 37650233

Group type: EXPERIMENTAL
Intervention: Delta variant infection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All variants (post-peak viral load)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: First-phase viral decline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Second-phase viral decline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo recipients
Number of subjects: 0
Study: 37650234

Group type: EXPERIMENTAL
Intervention: Investigational agents (specific agents not detailed)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pooled placebo control group
Number of subjects: 0
Study: 37650236

Group type: EXPERIMENTAL
Intervention: Bamlanivimab 700 mg
Number of subjects: 506
Study: 37650235

Group type: EXPERIMENTAL
Intervention: Antiviral treatment in outpatient trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Analysis methods (ANCOVA or MMRM) with singly imputed values
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Analysis methods (ANCOVA or MMRM) considering values <LLoQ as censored measurements
Number of subjects: 0
Study: 37650237

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study: 37650478

Group type: EXPERIMENTAL
Intervention: Elective neck dissection (ND)
Number of subjects: 2820

Group type: COMPARATOR
Intervention: Positron emission tomography (PET-CT) following chemoradiotherapy
Number of subjects: 2820
Study: 37650664

Group type: EXPERIMENTAL
Intervention: Emerging treatment options for cervical dysplasia and early cervical cancer, specific interventions not detailed.
Number of subjects: 0
Study: 37650734

Group type: EXPERIMENTAL
Intervention: Niraparib + Bevacizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Niraparib alone
Number of subjects: 0
Study: 37650754

Group type: EXPERIMENTAL
Intervention: Microablative fractional CO laser treatment
Number of subjects: 15
Study: 37650759

Group type: EXPERIMENTAL
Intervention: Yellow fever vaccine (17DD)
Number of subjects: 218
Study: 37650806

Group type: EXPERIMENTAL
Intervention: High Ventilation Mode
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control Group (Standard Ventilation Mode)
Number of subjects: 0
Study: 37650808

Group type: EXPERIMENTAL
Intervention: Prolonged Exposure for Primary Care (PE-PC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Best-practices Treatment as Usual (TAU)
Number of subjects: 0
Study: 37650957

Group type: EXPERIMENTAL
Intervention: Small nidus group (< 3 cm)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Higher stasis index in the feeding artery
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Higher stasis index in the draining vein
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Lower outflow gradient in the draining vein
Number of subjects: 90
Study: 37650981

Group type: EXPERIMENTAL
Intervention: Preoperative accelerated partial breast irradiation (APBI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Preoperative RT
Number of subjects: 0
Study: 37651075

Group type: EXPERIMENTAL
Intervention: Canadian Syncope Pathway (CSP) intervention
Number of subjects: 1002

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 1002
Study: 37651119

Group type: EXPERIMENTAL
Intervention: Psilocybin (25 mg)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Niacin (100 mg)
Number of subjects: 104
Study: 37651144

Group type: EXPERIMENTAL
Intervention: Proficiency-based progression (PBP) training
Number of subjects: 30

Group type: COMPARATOR
Intervention: Traditional simulation-based training (SBT)
Number of subjects: 30
Study: 37651172

Group type: EXPERIMENTAL
Intervention: Roadmap 2.0 app
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Positive psychology interventions (PPIs)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Caregiver involvement
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Connectivity with other patients
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Nutritional support intervention
Number of subjects: 17
Study: 37651174

Group type: EXPERIMENTAL
Intervention: Behavioral intervention to increase physical activity (PADL)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Educational program (group discussions and video presentations)
Number of subjects: 0
Study: 37651202

Group type: EXPERIMENTAL
Intervention: AFQ056
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 37651209

Group type: EXPERIMENTAL
Intervention: Tele-Retinal Imaging
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 37651261

Group type: EXPERIMENTAL
Intervention: Atezolizumab plus magrolimab
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Atezolizumab plus niraparib
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Atezolizumab plus tocilizumab
Number of subjects: 76

Group type: COMPARATOR
Intervention: Atezolizumab monotherapy
Number of subjects: 76
Study: 37651291

Group type: EXPERIMENTAL
Intervention: Patient and provider education
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transitional dialysis units and community dialysis houses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Home dialysis preference mandate and financial support
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Respite care and planned home-to-home transitions
Number of subjects: 0
Study: 37651373

Group type: EXPERIMENTAL
Intervention: High-dose TXA (20 mg/kg loading dose followed by 5 mg/kg/h continuous infusion)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-dose TXA (20 mg/kg loading dose followed by continuous infusion of normal saline)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (identical volume of normal saline)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 0
Study: 37651465

Group type: EXPERIMENTAL
Intervention: Multimorbidity clusters (Heart-liver-gastrointestinal) in males aged 81-90 years
Number of subjects: 14286

Group type: EXPERIMENTAL
Intervention: Multimorbidity clusters (Diabetes-cardiovascular) in females aged 81-95 years
Number of subjects: 14286

Group type: EXPERIMENTAL
Intervention: Multimorbidity clusters (Psychogeriatric) in females aged 81-95 years
Number of subjects: 14286

Group type: EXPERIMENTAL
Intervention: Overall severe infection in COVID-19 patients
Number of subjects: 14286

Group type: EXPERIMENTAL
Intervention: Overall mortality in COVID-19 patients
Number of subjects: 14286
Study: 37651553

Group type: COMPARATOR
Intervention: Exercise
Number of subjects: 8191

Group type: COMPARATOR
Intervention: Aromatherapy, massage, and acupressure
Number of subjects: 8191

Group type: COMPARATOR
Intervention: Pharmacological and other non-pharmacological interventions
Number of subjects: 8191
Study: 37651654

Group type: EXPERIMENTAL
Intervention: Interval-compressed chemotherapy
Number of subjects: 0
Study: 37651655

Group type: EXPERIMENTAL
Intervention: Tisotumab vedotin (TV) + Carboplatin (1L treatment); TV 2 mg/kg + Carboplatin AUC 5 on day 1 every 3 weeks
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Tisotumab vedotin (TV) + Pembrolizumab (1L treatment); TV 2 mg/kg + Pembrolizumab 200 mg on day 1 every 3 weeks
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Tisotumab vedotin (TV) + Pembrolizumab (2L/3L treatment); TV 2 mg/kg + Pembrolizumab 200 mg on day 1 every 3 weeks
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Tisotumab vedotin (TV) + Bevacizumab; TV 2 mg/kg + Bevacizumab 15 mg/kg on day 1 every 3 weeks
Number of subjects: 142
Study: 37651666

Group type: EXPERIMENTAL
Intervention: Medium cutoff membranes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-flux membranes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hemodialysis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hemodiafiltration
Number of subjects: 0
Study: 37651676

Group type: EXPERIMENTAL
Intervention: BEMPEG plus Nivolumab (NIVO)
Number of subjects: 783

Group type: COMPARATOR
Intervention: Nivolumab (NIVO) monotherapy
Number of subjects: 783
Study: 37651844

Group type: EXPERIMENTAL
Intervention: Oral fumarate therapy
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control cohort (healthy volunteers)
Number of subjects: 28
Study: 37651942

Group type: EXPERIMENTAL
Intervention: Manual pressure
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: ShotBlocker
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control
Number of subjects: 90
Study: 37651975

Group type: EXPERIMENTAL
Intervention: DHA plus piracetam
Number of subjects: 100

Group type: COMPARATOR
Intervention: Piracetam alone (control group)
Number of subjects: 100
Study: 37651979

Group type: EXPERIMENTAL
Intervention: High-GI Mediterranean diet
Number of subjects: 156

Group type: COMPARATOR
Intervention: Low-GI Mediterranean diet
Number of subjects: 156
Study: 37652068

Group type: EXPERIMENTAL
Intervention: Neurological Pupil index (NPi) assessment using automated pupillometry every 4 hours for the first 7 days after admission.
Number of subjects: 514

Group type: EXPERIMENTAL
Intervention: NPi assessment
Number of subjects: 514
Study: 37652094

Group type: EXPERIMENTAL
Intervention: Local budesonide therapy (budesonide and physiological saline nasal irrigations administered via three syringes of 20 ml in each nasal cavity in the morning and evening for 30 days)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Control group (similar protocol without budesonide)
Number of subjects: 123
Study: 37652136

Group type: EXPERIMENTAL
Intervention: Remotely-instructed home-based transcranial direct current stimulation
Number of subjects: 0
Study: 37652258

Group type: EXPERIMENTAL
Intervention: Tanezumab 2.5 mg
Number of subjects: 4541

Group type: EXPERIMENTAL
Intervention: Tanezumab 5 mg
Number of subjects: 4541

Group type: COMPARATOR
Intervention: NSAID
Number of subjects: 4541

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4541

Group type: EXPERIMENTAL
Intervention: Tanezumab
Number of subjects: 4541
Study: 37652303

Group type: EXPERIMENTAL
Intervention: Consolidation pembrolizumab after PBT reRT for locoregional recurrences of NSCLC
Number of subjects: 22
Study: 37652304

Group type: EXPERIMENTAL
Intervention: Proton Beam Therapy (PBT)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Intensity Modulated Radiation Therapy (IMRT)
Number of subjects: 105
Study: 37652356

Group type: EXPERIMENTAL
Intervention: Vaccine Acceptance Intervention (VAI) training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 37652360

Group type: EXPERIMENTAL
Intervention: 4-session web-based intervention (Partners Connect)
Number of subjects: 408

Group type: COMPARATOR
Intervention: Communication resources from the Gottman Institute website
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: CRAFT workbook
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Phone-based CRAFT
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Partners Connect
Number of subjects: 408
Study: 37652554

Group type: EXPERIMENTAL
Intervention: Ustekinumab (UST) 6 mg/kg intravenous at week 0 followed by 90 mg subcutaneous every 8 weeks from week 8 to week 24
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 37652593

Group type: EXPERIMENTAL
Intervention: Caregiver interviews and infant health, growth and neurodevelopmental assessments at 6, 12 or 18 months
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Neurodevelopmental assessments using standardised tools
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Direct measurement of growth and health indicators
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Assessment of neurological findings
Number of subjects: 362
Study: 37652677

Group type: EXPERIMENTAL
Intervention: Endoluminal radiofrequency ablation (RFA) plus stenting
Number of subjects: 161

Group type: COMPARATOR
Intervention: Stenting alone (control group)
Number of subjects: 161
Study: 37652822

Group type: EXPERIMENTAL
Intervention: mOPV1 at 6-10-14 weeks/fIPV at 6 weeks
Number of subjects: 1192

Group type: EXPERIMENTAL
Intervention: mOPV1 at 6-10-14 weeks/fIPV at 10 weeks
Number of subjects: 1192

Group type: COMPARATOR
Intervention: mOPV1 at 6-10-14 weeks
Number of subjects: 1192

Group type: COMPARATOR
Intervention: bOPV at 6-10-14 weeks
Number of subjects: 1192
Study: 37652823

Group type: EXPERIMENTAL
Intervention: NVX-CoV2373
Number of subjects: 911
Study: 37652841

Group type: EXPERIMENTAL
Intervention: Machine learning-based model for predicting 5-year weight loss trajectories after bariatric surgery
Number of subjects: 10231
Study: 37652940

Group type: EXPERIMENTAL
Intervention: HMO-Concentrate administered orally for 7 days
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: HMO-Concentrate incubated with cultured adult microbiota
Number of subjects: 32
Study: 37652990

Group type: EXPERIMENTAL
Intervention: Randomized treatment arm (specific treatments not detailed in the abstract)
Number of subjects: 3513
Study: 37653075

Group type: EXPERIMENTAL
Intervention: 1-year partially supervised physical activity intervention (≥2.5 hours of intense physical activity/week)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Control group continued exercise as usual
Number of subjects: 151
Study: 37653140

Group type: EXPERIMENTAL
Intervention: Bispecific antibodies targeting GPRC5D
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Molecular profiling of target genes
Number of subjects: 3
Study: 37653203

Group type: EXPERIMENTAL
Intervention: LungCARE
Number of subjects: 66

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 66
Study: 37653215

Group type: EXPERIMENTAL
Intervention: GLP-1RA + Met (liraglutide, 1.2-1.8 mg/day + Met 1500 mg/day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: CPA/EE + Met (2 mg/day CPA and 35 μg EE + Met 1500 mg/day)
Number of subjects: 60
Study: 37653218

Group type: EXPERIMENTAL
Intervention: Prophylactic low-dose hydrocortisone (HC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 37653269

Group type: EXPERIMENTAL
Intervention: ApoE4 carriers in the AD group (51.4%)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: ApoE4 carriers in the AD/DLB group (72.4%)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: High years of education (YOE) subgroup in DLB
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Aβ42 levels in DLB ApoE4-positive demented patients
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: ApoE4 presence
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: ApoE4
Number of subjects: 197
Study: 37653342

Group type: EXPERIMENTAL
Intervention: mRNA-1273.222
Number of subjects: 887

Group type: COMPARATOR
Intervention: mRNA-1273
Number of subjects: 887
Study: 37653378

Group type: EXPERIMENTAL
Intervention: Prednisone (PG)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (CG)
Number of subjects: 32
Study: 37653380

Group type: EXPERIMENTAL
Intervention: Minimally Invasive Total Gastrectomy (MITG)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Minimally Invasive Proximal Gastrectomy (MIPG)
Number of subjects: 60
Study: 37653397

Group type: EXPERIMENTAL
Intervention: 1L ribociclib + fulvestrant
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 37653422

Group type: EXPERIMENTAL
Intervention: Higher plasma interleukin-6 levels
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: HIV positive status
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Higher body mass index
Number of subjects: 128
Study: 37653447

Group type: EXPERIMENTAL
Intervention: Ticagrelor 60 mg
Number of subjects: 7035
Study: 37653460

Group type: EXPERIMENTAL
Intervention: Anterion®
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Argos®
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: IOLMaster® 700
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Pentacam® AXL
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: OcuScan® RxP
Number of subjects: 51
Study: 37653477

Group type: EXPERIMENTAL
Intervention: Smart Triage
Number of subjects: 0
Study: 37653525

Group type: EXPERIMENTAL
Intervention: High-Intensity Laser Therapy (HILT) and stretching exercises
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham High-Intensity Laser Therapy (sham HILT) and stretching exercises
Number of subjects: 0
Study: 37653536

Group type: EXPERIMENTAL
Intervention: Mother-Child Emotional Preparation (MCEP)
Number of subjects: 8
Study: 37653607

Group type: EXPERIMENTAL
Intervention: Surgical fixation
Number of subjects: 64

Group type: COMPARATOR
Intervention: Nonoperative management
Number of subjects: 64
Study: 37653641

Group type: EXPERIMENTAL
Intervention: Mother's milk (analyzed for cytokines and inflammatory markers)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Stool calprotectin levels (corresponding to milk samples)
Number of subjects: 92
Study: 37653767

Group type: EXPERIMENTAL
Intervention: Cecal retroflexion during colonoscopy
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (2 forward examinations only)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Cecal retroflexion
Number of subjects: 55
Study: 37653768

Group type: EXPERIMENTAL
Intervention: PP6M (700/1000 mg eq.)
Number of subjects: 90

Group type: COMPARATOR
Intervention: PP3M (350/525 mg eq.)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: PP6M
Number of subjects: 90

Group type: COMPARATOR
Intervention: PP3M
Number of subjects: 90
Study: 37653830

Group type: EXPERIMENTAL
Intervention: Preanesthesia assessment clinic (PAC)
Number of subjects: 30351

Group type: COMPARATOR
Intervention: No preanesthesia assessment clinic (non-PAC)
Number of subjects: 30351
Study: 37654065

Group type: EXPERIMENTAL
Intervention: Lumipulse assay for plasma pTau181
Number of subjects: 0

Group type: COMPARATOR
Intervention: Simoa assay for plasma pTau181
Number of subjects: 0
Study: 37654656

Group type: EXPERIMENTAL
Intervention: Tai Chi exercise (TC)
Number of subjects: 12
Study: 37654659

Group type: EXPERIMENTAL
Intervention: Non-invasive physical plasma (NIPP) treatment
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group (untreated patients)
Number of subjects: 63
Study: 37654667

Group type: EXPERIMENTAL
Intervention: Domiciliary transcutaneous electrical stimulation (TESLA)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 56
Study: 37654670

Group type: EXPERIMENTAL
Intervention: MaaT013 (pooled allogeneic faecal microbiota)
Number of subjects: 24
Study: 37654668

Group type: EXPERIMENTAL
Intervention: Monoclonal antibody treatment
Number of subjects: 1796

Group type: EXPERIMENTAL
Intervention: Corticosteroids therapy for mild/severe cases
Number of subjects: 1796

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 vaccination
Number of subjects: 1796

Group type: COMPARATOR
Intervention: Post-COVID-19 syndrome (PCS)
Number of subjects: 1796

Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 1796

Group type: EXPERIMENTAL
Intervention: Gastrointestinal symptoms during acute infection
Number of subjects: 1796

Group type: EXPERIMENTAL
Intervention: Renal complications during acute infection
Number of subjects: 1796

Group type: EXPERIMENTAL
Intervention: Vaccination
Number of subjects: 1796

Group type: EXPERIMENTAL
Intervention: Early treatment with monoclonal Ab
Number of subjects: 1796
Study: 37654895

Group type: EXPERIMENTAL
Intervention: Acetaminophen (APAP) + anti-PD-1 treatment (sintilimab)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Anti-PD-1 treatment (sintilimab) alone
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Acetaminophen (APAP)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Combination of APAP and anti-PD-1 treatment
Number of subjects: 39
Study: 37655106

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (13 patients)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Neoadjuvant immunotherapy (26 patients)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Neoadjuvant targeted therapy (9 patients)
Number of subjects: 48
Study: 37655205

Group type: EXPERIMENTAL
Intervention: selpercatinib treatment
Number of subjects: 77
Study: 37655258

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention in addition to optimal medical therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Coronary artery bypass grafting
Number of subjects: 0
Study: 37655616

Group type: EXPERIMENTAL
Intervention: STELLA-FTD intervention
Number of subjects: 16
Study: 37655691

Group type: EXPERIMENTAL
Intervention: pegcetacoplan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 37656041

Group type: EXPERIMENTAL
Intervention: Conventional RECIST assessment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Volumetric assessment of RECIST target lesions
Number of subjects: 0